Zhen Li
37Patents
5h-index
55Co-inventors
72Inventor score
Filing activity: Sep 12, 1997 → Dec 22, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7351725B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | Chemistry; Metallurgy | 17 | Expired |
| US10294474B2 | Targeting ligands | Chemistry; Metallurgy | 13 | Active |
| US7199142B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | Chemistry; Metallurgy | 12 | Expired |
| US10450565B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Physics | 7 | Active |
| US10662427B2 | Compositions and methods for inhibiting gene expression of LPA | Chemistry; Metallurgy | 5 | Active |
| US10246709B2 | Targeting ligands for therapeutic compounds | Chemistry; Metallurgy | 5 | Active |
| US8129111B2 | Fluorescent water-soluable conjugated polyene compounds that exhibit aggregation induced emission and methods of making and using same | Emerging Cross-Sectional Technologies | 4 | Active |
| US10780108B2 | RNAi agents for Hepatitis B virus infection | Emerging Cross-Sectional Technologies | 4 | Active |
| US9932586B2 | Compositions and methods for inhibiting gene expression of LPA | Chemistry; Metallurgy | 3 | Active |
| US10597657B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Chemistry; Metallurgy | 3 | Active |
| US7939613B2 | Fluorescent water-soluble conjugated polyene compounds that exhibit aggregation induced emission and methods of making and using same | Physics | 2 | Active |
| US11203756B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Physics | 2 | Active |
| US11174481B2 | Targeting ligands | Chemistry; Metallurgy | 2 | Active |
| US6329393A | Crystalline pharmaceutically acceptable salts of an oxazolidinone derivative | Human Necessities | 1 | Expired |
| US6201158A | Process for making intermediate aldehydes | Chemistry; Metallurgy | 1 | Expired |
| US11180529B2 | Alpha-v beta-6 integrin ligands and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US11214801B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Chemistry; Metallurgy | 1 | Active |
| US10590416B2 | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | Chemistry; Metallurgy | 1 | Active |
| US11884920B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Physics | 0 | Active |
| US12116573B2 | Targeting ligands for therapeutic compounds | Chemistry; Metallurgy | 0 | Active |
| US6201115A | Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications | Chemistry; Metallurgy | 0 | Expired |
| US11597701B2 | Integrin ligands and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US7879875B2 | P38 kinase inhibiting agents | Human Necessities | 0 | Active |
| US11517584B2 | RNAi agents for Hepatitis B virus infection | Emerging Cross-Sectional Technologies | 0 | Active |
| US12365899B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.